Conferences - Results from #360

Viewing 361-380 of 11531 articles

AUA 2024: The Added Value of Concomitant Whole-Pelvis Salvage Radiation Therapy in Oligo-Recurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy for Distant Positive Uptakes at PSMA PET

AUA 2024: Development of a Prediction Model of Survival Amongst Patients with Metastatic Hormone Sensitive Prostate Cancer Using Big Data: Interim Results from the European Network of Excellence for Big Data in Prostate Cancer (PIONEER)

AUA 2024: A Multi-Center Randomized Controlled Trial Of Ambulatory Versus Inpatient Percutaneous Nephrolithotomy

AUA 2024: Outcomes for Localized Renal Cell Carcinoma Patients on Immunosuppression Following Organ Transplantation

AUA 2024: Does Deep Learning Reconstruction Improve Ureteral Stone Detection and Subjective Image Quality in the CT Images of Patients with Metal Hardware?

AUA 2024: The Role of PSA Doubling Time in the Stratification of Patients with a Negative PSMA PET After Biochemical Recurrence of Prostate Cancer: Implications for Tailored Salvage Treatment Strategies

AUA 2024: Evaluating the Role of Telemedicine in Reducing Racial and Ethnic Disparities in Prostate Cancer Care

AUA 2024: Descriptive Tumor Characteristics of 992 Consecutive Patients Who Underwent Staging with PSMA PET/CT Before Radical Prostatectomy.

AUA 2024: Greening the Operating Room (GOR): High-Impact Initiatives Urologists’ Can Facilitate to Jumpstart a Program

AUA 2024: ARV-766, a PROTAC Androgen Receptor Degrader, Combined with Abiraterone in Novel Hormonal Agent (NHA)-Naïve Metastatic Prostate Cancer: Phase 1 Cohort (Part C) of a Phase 1/2 Study

AUA 2024: Determinants of Financial Toxicity in Patients with Urologic Cancer

AUA 2024: Impact of 18F-DCFPyL on Accuracy of mpMRI in Men with Low and Intermediate Risk Prostate Cancer: Interim Analysis of a Phase II Diagnostic Trial

AUA 2024: A Phase II Trial of Intravesical Gemcitabine and Docetaxel (GEMDOCE) in the Treatment of BCG-Naïve Non-Muscle Invasive Urothelial Carcinoma of the Bladder

AUA 2024: Comparison of BCG to Gemcitabine/Docetaxel in The Intermediate Risk Group Composed Mostly of TaHG

AUA 2024: The Impact of Delayed Administration of Androgen-Receptor Signaling Inhibitors (ARSI) on Prognosis for mHSPC

AUA 2024: Urinary Minimal Residual Disease Detection Predicts Recurrence in BCG-Unresponsive NMIBC and Quantifies Molecular Response to Nadofaragene Firadenovec

AUA 2024: Paradigm-Shifting, Practice-Changing Clinical Trials in Urology: PSMAfore: Efficacy of 177Lu-PSMA-617 Versus ARPI Change in Taxane-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer by Pre-Randomization ARPI

AUA 2024: Paradigm-Shifting, Practice-Changing Clinical Trials in Urology: Apalutamide and ADT for the Treatment of High-Risk Localized Prostate Cancer Following Radical Prostatectomy in Apa-RP: A Multicenter, Open-Label, Single Arm Trial

AUA 2024: Spatial Analysis of The Tumor Immune Microenvironment in Papillary Renal Cell Carcinoma

AUA 2024: TAR-200 in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results from the SunRISe-1 Study

14
15
16
17
18
19
20
21
22
23